SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success
Stocktwits · 7d ago
Space Coast launch schedule
Orlando Sentinel · 7d ago
NITRO CIRCUS TAKES DINNER TO NEW HEIGHTS WITH WORLD-FIRST "DINNER FOR 6" SKYDIVING STUNT
PR Newswire · 6d ago
Delivra Health Brands Launches LivRelief (TM) Itch Relief Cream in the Canadian Market
TMX Newsfile · 7d ago
Florida Tech board elects Dreggors to second term
Florida Today · 7d ago
ASTS Stock Eases After 3-Day Run: FCC Opens Door For Direct Phone-To-Satellite Connectivity Using 800 MHz Spectrum
Stocktwits · 7d ago
Quote and historical data from Yahoo Finance. Delayed at least 15 minutes for non-index symbols. Provided for informational purposes only; not investment advice.